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Abstract Antimicrobial peptides (AMPs) are small cationic molecules best known as mediators
of the innate defence against microbial infection. While in vitro and ex vivo evidence suggest
AMPs’ capacity to kill cancer cells, in vivo demonstration of an anti-tumour role of endogenous
AMPs is lacking. Using a Drosophila model of tumourigenesis, we demonstrate a role for the AMP
Defensin in the control of tumour progression. Our results reveal that Tumour Necrosis Factor
mediates exposure of phosphatidylserine (PS), which makes tumour cells selectively sensitive to the
action of Defensin remotely secreted from tracheal and fat tissues. Defensin binds tumour cells in
PS-enriched areas, provoking cell death and tumour regression. Altogether, our results provide the
first in vivo demonstration for a role of an endogenous AMP as an anti-cancer agent, as well as a
mechanism that explains tumour cell sensitivity to the action of AMPs.
DOI: https://doi.org/10.7554/eLife.45061.001
Introduction
Vast amount of evidence demonstrates the key role of systemic immunity in tumour progression and
patient outcome. Efforts to manipulate the immune response to tumours are at the core of basic
and translational cancer research. In mammals and flies, tumourigenesis triggers inflammation and
activation of the immune system, leading to tumour cell death (Cordero et al., 2010;
Parameswaran and Patial, 2010; Parisi et al., 2014; Teng et al., 2008). Tumour Necrosis Factor
(TNF) is an important player in these tumour/immune interactions and has pleiotropic effects on
tumours, including induction of cell death (Ham et al., 2016; Parameswaran and Patial, 2010). This
function is conserved in Drosophila, where the single TNF homolog Eiger (Egr), produced by
tumour-associated macrophages (TAMs), has been shown to drive cell death of neoplastic tumours,
generated in larval imaginal discs by the loss of apico-basal complex components such as Disc large
1, Scribble or Lethal giant larvae (Cordero et al., 2010; Parisi et al., 2014; Parvy et al., 2018).
Moreover, we have previously reported that tumours from disc large 1 Drosophila mutant larvae
(dlg40.2 hereafter referred to as dlg), activate Toll pathway in the Drosophila fat body in an Egr-
dependent manner, and this immune activation is necessary for TNF-dependent tumour cell death
(Parisi et al., 2014). However, the mechanisms by which activation of an immune response in the fat
body executes tumour cell death remain unknown (Figure 1A).
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In Drosophila as in mammals, Toll pathway is well known to play a central role in the innate
immune response to infection (Lemaitre et al., 1996). Downstream effectors of the Toll pathway
include antimicrobial peptides (AMPs), which possess microbicidal activities against various patho-
gens. They display potent antimicrobial activity in vitro by disrupting negatively-charged microbial
membranes. While intracellular activities have been reported, many AMPs kill pathogens by inserting
into the lipid bilayer and disrupting the membrane integrity (Brogden, 2005). Host cells are instead
protected from AMP as they are positively charged and contain cholesterol (Brender et al., 2012).
In vitro studies have revealed AMPs capacity to kill cancer cells (Deslouches and Di, 2017). How-
ever, whether this cancer-killing activity is a natural function of AMPs is unknown, as there are no
reports on an in vivo paradigm addressing such question. Since the Toll pathway is activated in dlg
mutant tumour bearing larvae and is required for optimal TNF-induced tumour cell death
(Parisi et al., 2014), we hypothesised that AMPs may be involved in this process.
Here we show that Drosophila defensin is induced in the fat body and tracheal system of dlg
mutant tumour bearing larvae. We find Defensin consistently associated to dying tumour cells. Criti-
cally, systemic and tissue specific knockdown of Defensin demonstrates a non-redundant role of the
AMP in controlling tumour growth through the induction of tumour cell death. Anti-tumoural Defen-
sin production relies on TNF-dependent activation of both Toll and Imd pathway. Our results dem-
onstrate that dlg mutant tumours expose PS in response to haemocyte-derived TNF and that
Defensin is present in PS enriched area on the tumour surface. Finally, we find that lack of TNF pre-
vents PS exposure in tumours and makes them insensitive to the action of Defensin. Collectively, our
results reveal an anti-tumoural role for Defensin in vivo and provide insights into the molecular mech-
anisms, which make tumours sensitive to the killing action of an endogenous AMP.
eLife digest Animals have a natural defence system – the immune system – that is needed to
fight off disease-causing microbes, known as pathogens. One way the immune system attacks
pathogens is by producing small microbe-killing molecules called antimicrobial peptides. These
antimicrobial peptides carry a positive charge, which allows them to interact with and disrupt the
negatively charged cell surfaces of many microbes. Healthy animal cells do not have these negatively
charged components on their cell surface, which means they are invisible to antimicrobial peptides.
Studies have reported that antimicrobial peptides can attack cancer cells grown in a dish. However,
it was unclear whether they could fight cancer cells in a live animal.
Parvy et al. have now addressed this issue by studying tumours in the larvae of fruit flies. Flies
with tumours made an antimicrobial peptide called Defensin, which normally helps to fight
infections. When Parvy et al. deleted the gene coding for Defensin, less tumour cells were dying and
the tumours became bigger. This result indicated that Defensin was protecting the fruit flies from
tumours. Examining the tumours under the microscope showed that Defensin protein interacted
with the membranes of tumour cells. Defensin was not, however, interacting with healthy cells.
Further analysis revealed that a negatively charged component of cell membranes called
phosphatidylserine, which normally faces the inside of healthy cells, is exposed to the outer surface
of tumour cells. This negatively charged molecule renders cancer cells visible to positively charged
Defensin. Importantly, the exposure of the phosphatidylserine is mediated by the fly equivalent of a
protein called Tumour Necrosis Factor, a key player in cancer biology. Defensin binding to tumour
cells leads to their death.
These experiments in the fruit fly highlight key molecular mechanisms that allow antimicrobial
peptides to fight cancer cells in a living organism. Because human tumour cells can also expose
phosphatidylserine, these latest findings may open up the possibility of a new kind of anti-cancer
therapy for patients.
DOI: https://doi.org/10.7554/eLife.45061.002
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Figure 1. def is induced in dlg mutant tumour bearing animals. (A) Working model showing the cooperation between haemocyte-derived TNF and the
immune response in the fat body in tumour cell death (Parisi et al., 2014). (B) RT-qPCR analyses showing expression of several AMPs in the fat body of
dlg40.2 mutant tumour bearing larvae compared to wild-type (w1118) larvae (n = 4). (C) RT-qPCR analysis of def expression in w1118 and dlg40.2 whole
larvae reared on antibiotics (n = 7). (D) RT-qPCR analysis showing def expression in larvae expressing a ctrl-IR or a dlg-IR in the posterior part of the
wing disc (en>;UAS-dcr2) (n = 3). (E) Schematic representation of the def gene locus showing mutant alleles generated (UTR: Untranslated Regions, SP:
Signal Peptide, PrD: Pro-Domain, Def: Mature Defensin). Statistical analysis: B-D, Student t-test, B, ***p=0.0003, C, **p=0.0074, D, *p=0.042.
DOI: https://doi.org/10.7554/eLife.45061.003
The following figure supplement is available for figure 1:
Figure supplement 1. def mediates animal survival to infection by Gram-positive bacteria.
DOI: https://doi.org/10.7554/eLife.45061.004
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Results
dlg tumour bearing larvae express the AMP defensin
In order to assess expression of several AMPs we performed RT-qPCR analysis on fat bodies dis-
sected from wild type controls (w1118) or dlg mutant larvae (Figure 1B). Results showed consistent
and statistically significant upregulation of defensin in fat bodies of dlg larvae compared to wild-
type ones (Figure 1B). Other Toll-dependent AMPs display a trend to be increased (drosomycin and
attacin A), even though data were highly variable amongst biological replicates, while other AMPs
were not transcriptionally regulated (drosocyn, cecropin A1) (Figure 1B). Interestingly, human b-
Defensin-1 displays anticancer activity in vitro (Bullard et al., 2008; Sun et al., 2006), and deletion
of human def appears prevalent in some cancer types (Ye et al., 2018). This prompted us to explore
the role of Drosophila Defensin in dlg mutant tumours. Using dlg larvae reared on antibiotics, we
confirmed that defensin upregulation was independent of the presence of microbes (Figure 1C).
Moreover, larvae bearing dlg imaginal discs tumours induced by RNAi (en >UAS-dcr2; UAS-dlg-IR)
also displayed increased defensin expression, confirming def gene induction as a consequence of
dlg-driven epithelial transformation rather than whole body dl loss (Figure 1D). We conclude that
Defensin, an AMP known for its activity against microbes, is induced, in a sterile environment, by the
presence of tumours.
Defensin restrains dlg tumour growth and promotes tumour cell death
We next hypothesised that Defensin may be an important mediator of anti-tumour immunity in vivo.
To test this hypothesis, we generated null mutant alleles for the defensin (def) gene using the
CRISPR/Cas9 system (defsk3 and defsk4) (Figure 1E) (Hanson et al., 2019). Survival analysis of defsk3
flies confirmed that this AMP contribute to resist systemic infection to certain Gram-positive bacteria
(Figure 1—figure supplement 1) (Levashina et al., 1995). To evaluate the effect of Defensin on
tumour development, we combined def and dlg loss of function alleles. Compared to dlg mutant
animals, dlg;def double mutants displayed a significant increase in tumour size (Figure 2A). Tumour
growth is limited by apoptotic tumour cell death as revealed by Dcp1 staining (Parisi et al., 2014).
Interestingly, tumours from dlg;def double mutants display a very strong decrease in apoptosis
(Figure 2B–E’), suggesting that increased tumour size in absence of Defensin is due to a decrease in
tumour cell death. This was further supported by the similar proliferation rates measured in dlg and
dlg,def mutant tumours as per quantification of anti-phophoHistone H3 staining (Figure 2—figure
supplement 1A–E’). Importantly, the effect of Def on tumour size and cell death were still observed
when dlg and dlg,def larvae were reared in sterile conditions (Figure 2—figure supplement 1F–J’)
and further confirmed upon ubiquitous knock down of def using RNA interference (IR) (Figure 2F–
J’). Furthermore, fat body overexpression of def significantly rescued tumour volume and tumour
cell death of dlg;defsk3 double mutant animals (Figure 2K and L). Additionally, larval injection of a
synthetic Defensin peptide increased tumour cell death of dlg or dlg;defsk3 imaginal discs
(Figure 2M), while it had no effect on tissues from wild-type larvae, indicating that Defensin can
selectively promote cell death of tumour cells. Altogether, these results demonstrate that Defensin
is required to control dlg-dependent tumourigenesis in vivo through induction of tumour cell death.
Defensin remotely produced from immune tissues bind to tumour cells
Having shown that Defensin restrict tumour growth, we sought to determine the tissues that pro-
duced endogenous Defensin in the context of tumour bearing. Previous studies have shown that
Defensin is not produced by imaginal discs or tumours (Bunker et al., 2015; Ku¨lshammer et al.,
2015). In the context of infection, Defensin can be produced by the fat body as well the tracheal
and gut epithelium (Tzou et al., 2000). We monitored defensin expression by RT-qPCR in various
immune tissues of tumour bearing animals. We observed that the fat body, homologue to the mam-
malian liver and adipose tissue, and the trachea, a network of tubes transporting oxygen to cells that
resembles the mammalian vasculature, were the main sources of defensin in these animals
(Figure 3A). This was also supported by Defensin immunostaining, (Figure 3B and C). Transcript
assessment upon targeted IR knock down of defensin in the respective tissues further confirmed the
domains of endogenous gene expression (Figure 3D and I). Importantly, knocking down defensin
expression specifically in the fat body or the trachea of dlg animals, resulted in increased tumour
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Figure 2. Def restricts tumour growth and promotes tumour cell death. (A-E’) Quantification of tumour volume (TV) (A) and tumour cell death (TCD) (B)
in wing imaginal discs from dlg40.2 (n = 17), dlg40.2;defsk3 (n = 19) and dlg40.2;defsk4 (n = 20) mutant larvae and representative immunofluorescence
images of tissues quantified (C–E’). F, RT-qPCR analysis showing def expression upon ubiquitous knockdown (dlg40.2; tub>) (n = 3). G-J’, Quantification
of TV (G) and TCD (H) in wing imaginal discs from larvae ubiquitously expressing a control-IR (ctrl-IR: n = 10) or a def-IR (n = 15) and representative
Figure 2 continued on next page
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size and decreased tumour cell death (Figure 3E–H’ and J–M’) confirming the non-redundant func-
tional requirement of defensin in both tissues to efficiently promote tumour cell death.
To investigate the possibility that Defensin produced by the fat body and the trachea can specifi-
cally target tumour cells, we made use of an inducible haemagglutinin (HA) tagged form of Defensin
(UAS-def-HA). We noticed leaky HA protein expression in the tracheal system (Figure 4—figure sup-
plement 1A) but not in the fat body (Figure 4—figure supplement 1B) of animals carrying the UAS-
def-HA construct only. Therefore, we overexpressed UAS-def-HA in the fat body using a Gal4 spe-
cific driver (lpp >def HA), which resulted in significant upregulation of Defensin in the fat body (Fig-
ure 4—figure supplement 1D) when compared to control conditions (Figure 4—figure
supplement 1B), but also maintained the leaky expression of the transgene in the trachea (Fig-
ure 4—figure supplement 1C). Strikingly, overexpression of UAS-def-HA in the fat body resulted in
Defensin-HA immunostaining in transformed imaginal discs from dlg mutant animals (Figure 4A–A’’
and B–B’’) but not in normal tissues from dlg heterozygous animals (Figure 4C and C’).
Consistently, using anti-Defensin antibody, we observed endogenous Defensin staining on dlg
mutant tumour (Figure 4D–D’’ and E–E’’) but not in wild-type discs (Figure 4G,G’). Interestingly, we
observed Defensin preferentially bound to tumour areas enriched with apoptotic cells (Figure 4D–
D’’ and E–E’’). This was confirmed by quantification of the amount of Def staining colocalising with
Dcp1 staining (Figure 4F). High-resolution imaging showed Defensin enrichment at the membrane
of these dying cells (Figure 4H–H’’).
Altogether, these results show that Defensin produced by immune tissues selectively binds
tumour cells to target them for apoptosis.
Toll and Imd pathway contribute to Defensin expression in dlg mutant
larvae
defensin expression upon systemic infection relies on both Toll and Imd pathways (Lemaitre et al.,
1996; Leulier et al., 2000). While we previously showed that Toll pathway activation in dlg mutant
larvae is required to achieve maximal tumour cell death (Parisi et al., 2014), the involvement of the
Imd pathway in tumour bearing animals was still elusive. To assess the contribution of the Imd path-
way to both defensin expression and tumour burden, we analysed these two phenotypes in larvae
deficient for the Imd-pathway. We observed a 55–60% decrease in defensin expression in dlg
mutants carrying a loss of function allele affecting imd (dlg;imd1) (Figure 5A) or the gene encoding
the downstream transcription factor Relish (dlg;relE20) (Figure 5F). Consistently, analysis of tumour
phenotypes revealed increased tumour volume and decreased tumour cell death in dlg;imd1 and
dlg;relE20 animals when compared with dlg counterparts (Figure 5B–E’ and G–J’). Altogether, these
data demonstrate that the Imd pathway is required for defensin upregulation, impairment of tumour
growth and induction of tumour cell death in dlg mutant larvae.
Upon infection, AMP expression in the trachea exclusively relies on the Imd pathway (Tzou et al.,
2000). We therefore looked at defensin expression and tumour phenotype in dlg mutant larvae
where imd expression had been knocked down specifically within tracheal cells (dlg;btl >imd-IR). In
this setting, defensin expression was significantly reduced in the whole larvae (Figure 6A). Consis-
tently, tumour volume was increased while tumour cell death was decreased (Figure 6B–E’) showing
the requirement of Imd pathway in the tracheal system to control tumour burden.
Figure 2 continued
immunofluorescence images of tissues quantified (I–J’). K-L, Quantification of TV (K) and TCD (L) in wing imaginal discs from dlg mutant controls
(dlg40.2;lpp>: n = 28), dlg;defsk3 mutants controls (dlg40.2;defsk3;lpp>: n = 31) or dlg;defsk3 mutants expressing def in the fat body (dlg40.2;defsk3,UAS-def;
lpp>: n = 27). M, Effect of PBS (ctrl) or synthetic Def injection on TCD from wild-type larvae (w1118, ctrl: n = 10, Def: n = 9), dlg40.2 (ctrl: n = 10, Def:
n = 10) and dlg40.2;defsk3 (ctrl: n = 11, Def: n = 18) mutant larvae. Tissues were stained with 4’,6-diamidino-2-phenylindole (DAPI, blue) for nuclei
visualisation and with anti-cleaved Decapping protein 1 (Dcp1) antibody (red) to detect apoptotic cell death. Scale bars = 50 mm. Statistical analysis: A,
B, K, L, One way ANOVA, *p<0.05, ****p<0.0001; F, Student t-test, ****p<0.0001, G-H, Mann-Whitney test, G, **p=0.0054, H, ****p<0.0001; M, Two
way ANOVA (only relevant significant statistics are indicated), *p<0.05, ****p<0.0001.
DOI: https://doi.org/10.7554/eLife.45061.005
The following figure supplement is available for figure 2:
Figure supplement 1. Tumour suppression by Def is independent of infection and tumour cell proliferation.
DOI: https://doi.org/10.7554/eLife.45061.006
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Figure 3. Def from the trachea and the fat body mediates tumour cell death. (A) RT-qPCR analysis of def
expression in gut, fat body and trachea dissected from w1118 or dlg40.2 mutant larvae (n = 3). B-C, Fat body (B) and
trachea (C) from dlg40.2 mutant larvae stained with DAPI (blue) and anti-Def antibody (red). D, RT-qPCR analysis of
def expression in dlg40.2 mutant larvae (dlg40.2;lpp>) expressing a ctrl-IR or def-IR in the fat body (n = 4). E-H’,
Figure 3 continued on next page
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In the fat body, both Imd and Toll pathways contribute to AMPs expression during infection
(Tzou et al., 2002). To evaluate the contribution of Toll and Imd pathways in fat body in tumour
bearing larvae, we monitored defensin expression and tumour phenotype in dlg animals in which
Toll or Imd pathways have been selectively knocked down in the fat body. Knocking down myd88,
which encodes a common adaptor to Toll receptors (Imler and Zheng, 2004), or imd in the fat body
resulted in a significant decrease in defensin expression (Figure 6F) and, consistently, increased
tumour volume and decreased tumour cell death (Figure 6G–K’). Moreover, concomitant overex-
pression of defensin and Myd88-IR or Imd-IR in the fat body of dlg larvae was sufficient to signifi-
cantly rescue the tumour volume and tumour cell death phenotypes resulting from fat body
knockdown of Myd88 or Imd in dlg animals (Figure 6L–O).
We conclude that, in dlg mutant animals, Toll and Imd pathways have non-redundant roles in
restricting tumour growth and promoting tumour cell death through the control of defensin expres-
sion. Importantly, forced defensin expression in an otherwise immune-compromised animal is suffi-
cient to reduce tumour growth and to promote tumour cell death.
Defensin is enriched in tumour areas exposing phosphatidylserine
AMPs targeting of pathogens, involves the recognition of negatively charged molecules exposed on
the cell surface (Yeaman and Yount, 2003). A key question raised by our study is how Defensin can
selectively bind and kill tumour cells (Figure 4 and Figure 2M). Selective action of cationic AMP is
attributed to their ability to interact with negatively charged membrane such as those found in bac-
teria. We hypothesised that the membrane of tumour cells from dlg mutant larvae might change
their electrostatic properties, making them sensitive to the action of Defensin. Phosphatidylserine
(PS) is a negatively charged phospholipid, normally restricted to the inner leaflet of the cell mem-
brane. However, PS can be exposed on the outer leaflet for example in apoptotic cells, which tags
these cells for phagocytosis (Birge et al., 2016; Shklyar et al., 2013; Tung et al., 2013). Moreover,
PS exposure has been shown to occur independently of apoptosis in many cancer cell types
(Riedl et al., 2011). Therefore, we investigated whether PS externalisation could be a factor allowing
specific targeting of tumour cells by Defensin. Our data revealed that dlg but not wild-type tissues,
displayed high levels of Annexin V staining (Figure 7A and F; compare to E), indicating increased
exposure of PS by dlg tumours. We next looked at the ability of Defensin to specifically associate
with tumour cells exposing PS and found that Defensin was enriched in Annexin V+ve areas on dlg
tumours (Figure 7A–A’’ and B–B’’). This was confirmed by quantification of the amount of Def stain-
ing colocalising with Annexin V staining (Figure 7C). Thus, Defensin produced by immune responsive
tissues binds specifically to tumour cells and this ability correlated with their exposure of PS.
The TNF homolog Eiger is required for PS exposure and defensin anti-
tumoural activity
Previous studies have shown that circulating macrophage-like cells in Drosophila, called haemocytes,
bind to dlg mutant tumours and contribute to cell death (Parisi et al., 2014). This process is medi-
ated by the release of Egr from haemocytes (Cordero et al., 2010; Parisi et al., 2014), which then
activates the JNK pathway in target cells to promote apoptosis (Igaki et al., 2009). Moreover, Toll
pathway activation in tumour bearing animals also requires Egr (Parisi et al., 2014). Accordingly, we
found that defensin upregulation observed in dlg animals was lost in dlg;egr3 double mutants
(Figure 7D). We next tested whether PS exposure in tumours was dependent on Eiger, and
Figure 3 continued
Quantification of TV (E) and TCD (F) in wing imaginal discs from dlg40.2 mutant larvae (dlg40.2;lpp>) expressing a
ctrl-IR (n = 15) or def-IR (n = 17) in the fat body and representative immunofluorescence images of tissues
quantified (G–H’). I, RT-qPCR analysis of def expression in dissected trachea from dlg40.2 mutant larvae (dlg40.2;
btl>) expressing a ctrl-IR or def-IR in the trachea (n = 3). J-M’, Quantification of TV (J) and TCD (K) in wing
imaginal discs from dlg40.2 mutant larvae (dlg40.2;btl>) expressing a ctrl-IR (n = 14) or def-IR (n = 16) in the trachea
and representative immunofluorescence images of tissues quantified (L–M’). Tumours were stained with DAPI
(blue) and anti-Dcp1 antibody (red). Scale bars = 50 mm. Statistical analysis: A, D, I, Student t-test, D, **p=0.0054, I,
****p<0.0001; E, F, J, K, Mann-Whitney test, E, F, ****p<0.0001, J, ***p=0.0009, K, ***p=0.0004.
DOI: https://doi.org/10.7554/eLife.45061.007
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Figure 4. Def produced by immune tissues specifically targets tumour cells. (A-A’’) DAPI (blue), anti-Dcp1 (green) and anti-HA antibody (red) staining of
dlg40.2 mutant tumour from larvae overexpressing a def-HA construct in the fat body and the trachea (dlg40.2;lpp >UAS-def-HA). B-B’’, Enlargement of
inset from A’’ (white outline) showing Dcp1 (B), Def-HA (B’) and merged channels (B’’). C-C’, DAPI (blue), anti-Dcp1 (green) and anti-HA antibody (red)
staining of dlg40.2 heterozygous wing disc from larvae overexpressing def-HA (dlg40.2/FM7;lpp >UAS-def-HA). D-D’’, dlg40.2 mutant tumour stained with
DAPI (blue), anti-Def (red) and anti-Dcp1 (green) antibodies. E-E’’, Enlargement of inset from D’’ (white outline) showing Dcp1 (E), Def (E’) and merged
channels (E’’). F, Quantification of colocalization between Def and Dcp1 staining (n = 10). G-G’, wild type (w1118) wing imaginal disc stained with DAPI
(blue), anti-Def (red) and anti-Dcp1 (green) antibodies. H-H’’, High-resolution imaging of a single dying tumour cell stained with DAPI (blue), anti-Def
(red) and anti-Dcp1 (green) antibodies. A, C, D, G, Scale bars = 50 mm; B, E, Scale bars = 10 mm; H, Scale bar = 2.5 mm. Statistical analysis: F, Student
t-test, **p=0.0093.
DOI: https://doi.org/10.7554/eLife.45061.008
The following figure supplement is available for figure 4:
Figure supplement 1. Characterisation of UAS-def-HA expression.
DOI: https://doi.org/10.7554/eLife.45061.009
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Figure 5. Imd pathway activation is required for def expression and Def-mediated tumour cell death. (A) RT-qPCR
analysis of def expression from dlg40.2 and dlg40.2;imd1 mutant larvae (n = 4). B-E’, Quantification of TV (B) and
TCD (C) in wing imaginal discs from dlg40.2 (n = 15) and dlg40.2;imd1 (n = 14) mutants larvae and representative
immunofluorescence images of tissues quantified stained with DAPI (blue) and anti-Dcp1 antibody (red) (D–E’). F,
RT-qPCR analysis showing def expression in dlg40.2 and dlg40.2; relE20 mutant animals (n = 5). G-J’, Quantification
of TV (G) and TCD (H) from dlg40.2 (n = 12) and dlg40.2;relE20 (n = 10) mutant larvae and representative pictures of
the corresponding tumours (I–J’). Scale bars = 50 mm. Statistical analysis: A, F, Student t-test, A, ***p<0.0003, F,
****p<0.0001; B, C, G, H, Mann-Whitney test, B, C, H, ****p<0.0001, G, **p=0.009.
DOI: https://doi.org/10.7554/eLife.45061.010
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Figure 6. Imd and Toll pathway activation are required in the trachea and the fat body to promote Defensin-
dependent tumour cell death. (A) RT-qPCR analysis of def expression from dlg40.2 mutant larvae (dlg40.2;btl>)
expressing a ctrl-IR or imd-IR in the trachea (n = 3). B-E’, Quantification of TV (B) and TCD (C) from dlg40.2 mutant
larvae (dlg40.2;btl>) expressing a ctrl-IR (n = 18) or imd-IR (n = 15) in the trachea and representative
Figure 6 continued on next page
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observed an almost complete loss of cell-surface PS in dlg;egr3 tumours (Figure 7E–G). Therefore,
Egr is required for PS exposure in these tumours. We then analysed PS exposure in dlg mutant
tumours, upon specific egr knockdown in haemocytes (dlg;hml >egr-IR), and observed a strong
decrease in cell surface-exposed PS compared to control tumours (dlg;hml >ctrl-IR) (Figure 7H–J).
This indicates that PS exposure in tumour cells is likely triggered by the release of Egr from haemo-
cytes. Finally, to further test the hypothesis that Def requires PS to bind to tumours, we assessed the
ability of overexpressed Def-HA to bind to dlg,egr3 mutant tumours. Consistently with the observed
basal and overexpressed Def-HA expression pattern in wild type tissues (Figure 4—figure supple-
ment 1), Def-HA was expressed in the trachea and fat body of dlg,egr3 mutant animals (Figure 7—
figure supplement 1A,B). However, we did not find any detectable association of Def-HA to the sur-
face of dlg,egr3 tumours (Figure 7—figure supplement 1C,C’).
Importantly, Egr-dependent signalling and PS exposure were intact in dlg;def and dlg;imd
mutants (Figure 7—figure supplement 2) indicating that both events precede the action of Defen-
sin in dlg tumours. To further assess whether Egr was required for Defensin-induced tumour cell
death, we injected synthetic Defensin peptide into control, dlg or dlg;egr3 mutant larvae. While,
Defensin injection was able to robustly promote tumour cell death in dlg mutant tumours, it was
unable to affect tumours derived from Egr-deficient animals, further demonstrating the requirement
of Egr for tumour cell death induced by Defensin (Figure 7K).
Finally, we tested whether the antitumoral action of Def extended to other tumour models. We
observed that tumours induced by the loss of scribble (scrib), another member of the same apico-
basal complex as dlg, showed significant cell surface PS exposure, which was Egr dependent (Fig-
ure 7—figure supplement 3A,A’; compare to Figure 7—figure supplement 3B,B’). Moreover, we
detected Def enrichment in areas positive for Dcp1 staining on scrib tumours (Figure 7—figure sup-
plement 3C–C’’ and D–D’’). Consistently, removing def from scrib mutant animals led to increase in
tumour volume and decrease in tumour cell death (Figure 7—figure supplement 3E–H’). Alto-
gether, these results show that the sensitivity to Def is not restricted to dlg mutant tumours but
might rather be a general feature of neoplastic growth induced by loss of cell polarity.
Discussion
While the role of antimicrobial peptides in innate immune defense has been well-recognised for dec-
ades (Bahar and Ren, 2013), recent reports revealed potential additional physiological functions of
AMPs, including ageing and neurodegeneration (Cao et al., 2014; Kounatidis et al., 2017;
Lezi et al., 2018), wound-healing (Chung et al., 2017; Tokumaru et al., 2005), resistance to oxida-
tive stress (Mergaert et al., 2017; Zhao et al., 2011), immune signaling (Tjabringa et al., 2003;
van Wetering et al., 2002) and anti-cancer activity (Deslouches and Di, 2017). However, due to the
absence of AMP mutants, most of these studies have relied on the use of exogenous sources of
AMPs or genetic modification of upstream regulators of AMP expression. Recently, the use of loss
of function alleles of Drosophila Diptericin (DptB), allowed to establish a role for the AMP in long-
term memory (Barajas-Azpeleta et al., 2018). Pioneer work reporting systematic deletion of multi-
ple AMPs in Drosophila, opens the door for in-depth analysis of the endogenous functions of these
molecules (Hanson et al., 2019). Using such tools and a genetically defined in vivo tumour model,
our study demonstrates a role for Defensin in the control of tumours and deciphers the molecular
Figure 6 continued
immunofluorescence images of tissues quantified stained with DAPI (blue) and anti-Dcp1 antibody (red) (D–E’). F,
RT-qPCR analysis of def expression from dlg40.2 mutant larvae (dlg40.2;lpp>) expressing a ctrl-IR, an imd-IR or a
myd88-IR in the fat body. G-K’, Quantification of TV (G) and TCD (H) from dlg40.2 mutant larvae (dlg40.2;lpp>)
expressing a ctrl-IR, an imd-IR or a myd88-IR in the fat body and representative immunofluorescence images of
tissues quantified (I–K’). L-O, Quantification of TV (L, N) and TCD (M, O) from dlg40.2 mutant larvae (dlg40.2;lpp>)
expressing a ctrl-IR, an imd-IR alone or in combination with a UAS-def in the fat body (L, M) and from dlg40.2
mutant larvae (dlg40.2;lpp>) expressing a ctrl-IR, a myd88-IR alone or in combination with a UAS-def in the fat body
(N, O). Scale bars = 50 mm. Statistical analysis: A, Student t-test, A, ***p=0.0001; B, C, Mann-Whitney test, B,
***p=0.0003, C, ***p=0.0002; F, G, H, L-O, One way ANOVA, *p<0.05, **p<0.01, ****p<0.0001.
DOI: https://doi.org/10.7554/eLife.45061.011
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Figure 7. TNF is required for PS exposure and Defensin-driven tumour cell death. (A-A’’) DAPI (blue), Annexin V (green) and anti-Def (red) staining of
dlg40.2 mutant tumours. (B-B’’) Enlargement of inset from A’’ (white outline) showing Annexin V (B), Def (B’) and merged channels (B’’). (C)
Quantification of colocalisation between Def and Annexin V staining (n = 18). (D) RT-qPCR analysis showing def expression in wild-type, dlg40.2 or
dlg40.2;egr3 mutants. (E- G) Annexin V (green) and DAPI (blue) staining of wing imaginal discs from larvae of the indicated genotypes. (H, I) Annexin V
Figure 7 continued on next page
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mechanism allowing specific tumour cell targeting by the AMP. Collectively, our results suggest that
the two branches of Drosophila innate immunity contribute to tumour elimination (Figure 7L). The
cellular immune response to tumours involves the binding of haemocytes to tumour cells and activa-
tion of TNF pathway leading to PS exposure (Figure 7L). This is followed by a humoral response in
distant tissues (fat body and trachea) that triggers tumour cell death through the action of Defensin
(Figure 7L).
A role for a Drosophila AMP in tumour control
Using mutants as well as ubiquitous or targeted knockdowns, our study reveals that Defensin is non-
redundantly required to drive tumour cell death and restrict tumour growth in neoplastic tumours
generated by loss the apico-basal determinant Dlg and Scrib. This was reinforced by detection of
Defensin on dying tumour cells as well as genetic rescue and injection experiments showing that
Defensin can actively drive tumour cell death. Several in vitro studies in mammals have pointed to
AMPs anti-tumoural potential (Deslouches and Di, 2017). Amongst these suggested anticancer pep-
tides, Human b-Defensin-1 (hBD1) appears downregulated in 82% of prostate cancer and 90% of
renal clear cell carcinomas (Donald et al., 2003). Furthermore, expression of hBD1 induces cell
death in prostate and renal cancer cells in vitro (Bullard et al., 2008; Sun et al., 2006). Moreover, a
recent report shows prevalent deletion of Human defensin gene cluster in some tumour types includ-
ing prostate, lung and colorectal cancers, as well as a decrease overall survival in patients carrying
these deletions (Ye et al., 2018). However, since the classification of a molecule as AMP is based on
structural protein features, it is important to mention that Human Defensins are not homologous of,
but rather have structural resemblances, to Drosophila AMPs due to convergent evolution
(Shafee et al., 2017). Further studies are required to determine if anticancer activity displayed by
Defensins from different species is linked to their structural properties.
As upon infection (Tzou et al., 2000), we show that the fat body and the trachea are the main
sources of Defensin in tumour bearing larvae. Moreover, our results indicated that Defensin’s maxi-
mal expression and anti-tumour properties rely on Imd and Toll pathways activation. As expected
from previous studies on anti-pathogenic immunity, Imd appears to play a critical role in the tracheal
system, while both Imd and Toll drive Defensin expression in the fat body (Hoffmann and Reichhart,
2002; Tzou et al., 2002). Consistently, overexpressing Defensin partially rescued the effect of Imd
or Toll knockdown on dlg tumours. However, Toll and Imd pathways are major regulators of multiple
AMPs in the Drosophila fat body. Then, it is conceivable that AMPs other than Defensin may possess
similar anti-tumoural activity. In fact, a recent study in Drosophila shows that ectopic expression of
several antimicrobial peptides, including Defensin, can increase cell death in a haematopoietic
tumour model (Araki et al., 2019). Authors of that study also reported activation of Toll and Imd
pathways together with increased expression of several AMPs in those tumour bearing animals.
Together with our study, this suggests potentially general anti-tumoural properties of Drosophila
AMPs.
Figure 7 continued
(green) and DAPI (blue) staining of wing imaginal discs from dlg mutant larvae (dlg40.2,hml>) expressing a ctrl-IR (n = 5) or an egr-IR (n = 9) in the
haemocytes. (J) Quantification of Annexin V signal on tumours from the corresponding genotypes. (K) Quantification of TCD upon PBS (ctrl) or Def
injection in wild-type (w1118, ctrl: n = 10, Def: n = 14), dlg40.2 (ctrl/Def: n = 18) or dlg40.2;egr3 (ctrl: n = 20, Def: n = 13) mutant larvae. (L) A model for Def
antitumoural activity. A, E-I, Scale bars = 50 mm; B, Scale bars = 20 mm. Statistical analysis: C, Student t-test, ****p<0.0001; D, One way ANOVA,
*p<0.05; J, Mann-Whitney test, ***p=0.001; K, Two way ANOVA (only relevant significant statistics are indicated), *p<0.05.
DOI: https://doi.org/10.7554/eLife.45061.012
The following figure supplements are available for figure 7:
Figure supplement 1. Def-HA does not associate to PS-negative egr-mutant tumours.
DOI: https://doi.org/10.7554/eLife.45061.013
Figure supplement 2. TNF signalling activation does not require functional def.
DOI: https://doi.org/10.7554/eLife.45061.014
Figure supplement 3. scrib mutant tumours expose PS in a TNF-dependent manner and are sensitive to Def action.
DOI: https://doi.org/10.7554/eLife.45061.015
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Defensin specifically targets tumour cells
Importantly, we show that Defensin targets tumour cells for apoptosis while sparing normal cells. As
their human counterparts, we show that Drosophila tumours can expose PS independently of cell
death (Riedl et al., 2011). Interestingly, an in vitro study showed selective anticancer activity of
some synthetic peptides derived from beetle Defensin, against cancer cells exposing PS
(Iwasaki et al., 2009). A similar targeting mechanism has also been proposed to explain temporin-
1CEa or L-K6 anticancer activities towards melanoma cells and breast cancer cells respectively
(Wang et al., 2016; Wang et al., 2017). PS is a mark of apoptotic cells, which is used as an ‘eat me’
signal by phagocytes (Shklyar et al., 2013; Tung et al., 2013). In Drosophila, the phagocytic recep-
tor Simu together with Draper contribute to the elimination of apoptotic cells through recognition of
PS (Shklyar et al., 2013; Tung et al., 2013). It would be interesting to test the role of these recep-
tors in the control of tumour progression in Drosophila.
Our results indicate that PS exposure precedes Defensin action and is not just an ‘eat-me’ signal
but likely contributes to changing the membrane of tumour cells making them sensitive to the action
of AMPs. It is tempting to speculate that the deleterious effect of AMPs observed upon ageing or
neurodegeneration may involve a similar targeting mechanism of ‘foreign-looking’ or unfit cells
(Cao et al., 2013; Kounatidis et al., 2017; Lezi et al., 2018).
Noteworthy, other negatively charged molecules enriched on tumour surface such as heparan sul-
fates and O-glycosylated mucins may also contribute to the targeting by AMPs (Hollingsworth and
Swanson, 2004; Knelson et al., 2014).
Defensin action requires TNF
TNF is a major player in the tumour microenvironment by exerting pleiotropic effects on both the
tumour and its surroundings (Ham et al., 2016; Parameswaran and Patial, 2010). In our dlg mutant
model, we observed that defensin induction requires TNF, supporting previous observations that
induction of innate immune response in tumour bearing animal relied on Egr produced by the
tumour (Parisi et al., 2014). Indeed, Toll activation in the fat body has been proposed to be a conse-
quence of tumour-derived TNF, which drives haemocyte proliferation leading to an increase in Toll
ligand Spatzle (Parisi et al., 2014). Whether Imd pathway is also indirectly activated by the changes
in immune cell activity in response to tumour or by alternative mechanisms remains an open
question.
Our results show that haemocyte-derived TNF is required for PS exposure by the tumour, a key
process for tumour targeting by Defensin. Consistently, haemocyte-derived TNF is shown to drive
cell death in dlg mutant tumours (Parisi et al., 2014). The precise molecular mechanisms driving PS
exposure downstream of TNF remain unknown. However, haemocyte-derived TNF, activates JNK
pathway, which triggers many changes in tumour cells including apoptosis (Igaki et al., 2002;
Moreno et al., 2002), ROS production (Fogarty et al., 2016; Santaba´rbara-Ruiz et al., 2015), loss
of cell polarity (Zhu et al., 2010), modification of extracellular matrix (Uhlirova and Bohmann,
2006), proliferation and cell migration (Beaucher et al., 2007; Igaki et al., 2006; Pastor-
Pareja et al., 2004; Srivastava et al., 2007). Mild activation of JNK on its own is insufficient to drive
PS exposure and tissue sensitivity to Defensin-induced cell death (data not shown). While a JNK-
independent role of Egr in PS exposure and sensitivity to the AMP cannot be ruled out, TNF might
also sensitise cells through activation of the JNK pathway (Cordero et al., 2010) and PS exposure,
thus providing a secondary sensitisation mechanism of tumour cells to the action of Defensin. Fur-
ther studies are needed to explore a potential link between JNK activation and PS exposure.
Another consequence of TNF-dependent JNK activation in tumours is the increased expression of
matrix metalloproteases (Mmps) by tumour cells (Uhlirova and Bohmann, 2006). Importantly, we
show that Mmp-1 induction and then JNK pathway activation are still present in tumour from larvae
devoided of Defensin. This demonstrates that TNF signalling acts upstream of Defensin. Mmps
degrade the basal membrane facilitating metastasis of primary tumour cells (Beaucher et al., 2007;
Pastor-Pareja et al., 2004; Srivastava et al., 2007). Interestingly, a study reported that human
Mmp-7 can cleave immature Defensins, promoting their activation (Wilson et al., 1999;
Wilson et al., 2009). Indeed, the pro-domain present in AMPs is thought to keep their in vivo activ-
ity silent, allowing local activation of AMP upon cleavage. While the mechanisms of Drosophila
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Defensin pro-domain cleavage remain unknown, it would be interesting to explore whether the
changes in the tumour microenvironment could also affect Defensin activation.
In conclusion, our study provides the first direct in vivo demonstration of the role of an endoge-
nous AMP as an anti-cancer agent in Drosophila. Our data point to a conserved mechanism of
tumour control by AMPs, a potent arm of the innate immune system. Importantly, we identify cellular
features within tumours, which may be predictive of their sensitivity to be targeted by AMPs. This
study provides a new paradigm to decipher the molecular mechanisms influencing anti-tumoural
functions of an AMP, which may extend to other non-canonical roles of AMPs, such as in ageing,
long-term memory and wound healing. Moreover, together with the new genetic tools allowing tar-
geting of all Drosophila AMPs (Hanson et al., 2019), our study establishes new bases to explore in
vivo a potential important natural mechanism of defence against tumours.
Materials and methods
Key resources table
Reagent type
(species) or resource Designation Source or reference Identifiers
Additional
information
Genetic
reagent
(Drosophila
melanogaster)
w1118 (Dewey et al., 2004) BDSC: 3605;
RRID:BDSC_3605
Genetic
reagent
(Drosophila
melanogaster)
w1118 iso (Ferreira et al., 2014) N/A
Genetic
reagent
(Drosophila
melanogaster)
dlg40.2/FM7 (Mendoza-Topaz et al., 2008) Flybase_FBal0240608
Genetic
reagent
(Drosophila
melanogaster)
FRT82B,scrib1/TM6 (Bilder et al., 2000) Flybase_FBal0103577
Genetic
reagent
(Drosophila
melanogaster)
egr3 (Igaki et al., 2002) Flybase_FBal0147163
Genetic
reagent
(Drosophila
melanogaster)
imd1 (Leulier et al., 2000) Flybase_
FBal0045906
Genetic
reagent
(Drosophila
melanogaster)
relE20 (Leulier et al., 2000) DGGR: 109927;
RRID:DGGR_109927
Genetic
reagent
(Drosophila
melanogaster)
defsk3 (Hanson et al., 2019) N/A
Genetic
reagent
(Drosophila
melanogaster)
defsk4 (Hanson et al., 2019) N/A
Genetic
reagent
(Drosophila
melanogaster)
btl-gal4,UAS-RFP/CyO Irene Miguel-Aliaga N/A
Continued on next page
Parvy et al. eLife 2019;8:e45061. DOI: https://doi.org/10.7554/eLife.45061 16 of 26
Research article Cancer Biology Developmental Biology
Continued
Reagent type
(species) or resource Designation Source or reference Identifiers
Additional
information
Genetic
reagent
(Drosophila
melanogaster)
lpp-gal4/TM6B (Brankatschk and Eaton, 2010) N/A
Genetic
reagent
(Drosophila
melanogaster)
tub-gal4 Bloomington
Drosophila
Stock Center
BDSC: 5138;
RRID:BDSC_5138
y(1)
w[*];
P{w[+mC]=tubP-GAL4}
LL7/TM3,
Sb(4)
Ser(1)
Genetic
reagent
(Drosophila
melanogaster)
hmlD-gal4,UAS-gfp Bruno Lemaitre N/A
Genetic
reagent
(Drosophila
melanogaster)
en-gal4 Bloomington
Drosophila
Stock Center
BDSC: 30564;
RRID:BDSC_30564
y1 w*; P{w + mW.
hs=en2.4 GAL4}e16E
Genetic
reagent
(Drosophila
melanogaster)
UAS-def IR Vienna Drosophila
Resource Centre
VDRC:
102437;
RRID:
Flybase_FBst0474306
P{KK111656}VIE-260B
Genetic
reagent
(Drosophila
melanogaster)
UAS-imd IR Vienna Drosophila
Resource Centre
VDRC:
101834; RRID:
Flybase_FBst0473707
P{KK109863}VIE-260B
Genetic
reagent
(Drosophila
melanogaster)
UAS-myd88 IR Vienna Drosophila
Resource Centre
VDRC:
25402; RRID:
Flybase_FBst0455868
w1118; P{GD9716}v25402
Genetic
reagent
(Drosophila
melanogaster)
UAS-dlg IR Vienna Drosophila
Resource Centre
VDRC:
41136; RRID:
Flybase_FBst0463952
w1118; P{GD4689}v41136/TM3
Genetic
reagent
(Drosophila
melanogaster)
UAS-egr IR Vienna Drosophila
Resource Centre
VDRC:
108814; RRID:
Flybase_FBst0480608
P{KK103432}VIE-260B
Genetic
reagent
(Drosophila
melanogaster)
UAS-w IR Bloomington
Drosophila
Stock Center
BDSC: 25785; RRID:BDSC_25785 y(1) v(1); P{y[+t7.7]
v[+t1.8]=TRiP.
JF01786}attP2
Genetic
reagent
(Drosophila
melanogaster)
UAS-def (Tzou et al., 2000) Flybase_FBal0145092
Genetic
reagent
(Drosophila
melanogaster)
UAS-def-3xHA FlyORF FlyORF: F002467;
RRID:Flybase_
FBal0298643
M{UAS-Def.ORF.
3xHA.GW}ZH-86Fb
Genetic
reagent
(Drosophila
melanogaster)
UAS-dcr2 Bloomington
Drosophila
Stock Center
BDSC: 24650;
RRID:BDSC_24650
w[1118]; P{w[+mC]
=UAS-Dcr-2.D}2
Genetic
reagent
(Drosophila
melanogaster)
spzM7 (Neyen et al., 2014) N/A
Antibody Anti-GFP
(Chicken polyclonal)
Abcam Cat# ab13970;
RRID:AB_300798
IF(1:4000)
Continued on next page
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Continued
Reagent type
(species) or resource Designation Source or reference Identifiers
Additional
information
Antibody Anti-Def
(Mouse polyclonal)
Dahua Chen
(Ji et al., 2014)
N/A IF(1:100)
Antibody Anti-HA
(Mouse monoclonal)
Cell Signaling
Technology
Cat# 2367,
RRID:AB_10691311
IF(1:1000)
Antibody Anti-dcp1
(Rabbit polyclonal)
Cell Signaling
Technology
Cat# 9578,
RRID:AB_2721060
IF(1:100)
Antibody Anti-phospho-
Histone H3
(Ser10)
(Rabbit polyclonal)
Cell Signaling
Technology
Cat# 9701,
RRID:AB_331535
IF(1:100)
Antibody Anti-phospho-
Histone H3
(Ser28)
(Rabbit polyclonal)
Cell Signaling
Technology
Cat# 9713,
RRID:AB_823532
IF(1:100)
Antibody Anti-Mmp1
(Mouse clonality
unknown)
Developmental
Studies
Hybridoma Bank
Cat# 3B8D12,
RRID:AB_579781
IF(1:10)
Antibody Anti-Chicken
IgY Alexa 488
(Goat polyclonal)
Molecular Probes Cat# A-11039,
RRID:AB_142924
IF(1:500)
Antibody Anti-Mouse
IgG Alexa 488
(Goat polyclonal)
Molecular Probes Cat# A-11029,
RRID:AB_138404
IF(1:500)
Antibody Anti-Mouse
IgG Alexa 594
(Goat polyclonal)
Molecular Probes Cat# A-11032,
RRID:AB_141672
IF(1:500)
Antibody Anti-Rabbit
IgG Alexa 488
(Goat polyclonal)
Molecular Probes Cat# A-11008,
RRID:AB_143165
IF(1:500)
Antibody Anti-Rabbit
IgG Alexa 594
(Goat polyclonal)
Thermo Fischer
Scientific
Cat# A-11037,
RRID:AB_2534095
IF(1:500)
Sequence-
based reagent
rpl32-fwd This paper PCR primers AGGCCCAAGATCGTGAAGAA
Sequence-
based reagent
rpl32-rev This paper PCR primers TGTGCACCAGGAACTTCTTGA
Sequence-
based reagent
def-fwd This paper PCR primers CTTCGTTCTCGTGGCTATCG
Sequence-
based reagent
def-rev This paper PCR primers ATCCTCATGCACCAGGACAT
Sequence-
based reagent
def-PCR-fwd This paper PCR primers TTATTGCAGAAACGGGCTCT
Sequence-
based reagent
def-PCR-rev This paper PCR primers ATGGTAAGTCGCTAACGCTAATG
Sequence-
based reagent
def-seq This paper Sequencing primers CGTGTCTTCCTGCACAGAAA
Sequence-
based reagent
attA-fwd This paper PCR primers ATGCTCGTTTGGATCTGACC
Sequence-
based reagent
attA-rev This paper PCR primers TCAAAGAGGCACCATGACCAG
Sequence-
based reagent
cecA1-fwd This paper PCR primers CTCAGACCTCACTGCAATAT
Sequence-
based reagent
cecA1-rev This paper PCR primers CCAACGCGTTCGATTTTCTT
Continued on next page
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Continued
Reagent type
(species) or resource Designation Source or reference Identifiers
Additional
information
Sequence-
based reagent
dro-fwd This paper PCR primers CGTTTTCCTGCTGCTTGCTT
Sequence-
based reagent
dro-rev This paper PCR primers GGCAGCTTGAGTCAGGTGAT
Sequence-
based reagent
drs-fwd This paper PCR primers CTCTTCGCTGTCCTGATGCT
Sequence-
based reagent
drs-rev This paper PCR primers ACAGGTCTCGTTGTCCCAGA
Peptide,
recombinant protein
Drosophila
endogenous
Defensin
Bulet EIRL N/A
Peptide,
recombinant protein
Drosophila
Synthetic
Defensin
Genepep N/A ATCDLLSKWNWNHTACAGH
CIAKGFKGGYCNDKAVCVCRN
Commercial
assay or kit
High Capacity
cDNA Reverse
Transcription Kit
Applied Biosystems Cat# 4368813
Commercial
assay or kit
PerfeCTa SYBR
Green FastMix
(Low ROX)
Quanta Bio Cat# 95074–012
Commercial
assay or kit
TRIzol Reagent Thermo
Fisher Scientific
Cat# 15596018
Commercial
assay or kit
Turbo DNA free Kit Life Technologies LTD Cat# AM1907
Commercial
assay or kit
High Capacity
cDNA Reverse
Transcription Kit
Applied Biosystems Cat# 4368813
Chemical
compound, drug
40,6-Diamidine-20
-phenylindole
dihydrochloride (DAPI)
Sigma Cat# D9542 1 mg/mL
Software,
algorithm
Fiji NIH https://fiji.sc/
Software,
algorithm
GraphPad Prism 6 GraphPad RRID:SCR_002798
Software,
algorithm
7500 Real-Time
PCR Software
Applied Biosystems RRID:SCR_014596
Software,
algorithm
BatchQuantify (Johansson
et al., 2019)
https://github.
com/emltwc/
2018-Cell-Stem-Cell
Software,
algorithm
GraphPad Prism 6 GraphPad RRID:SCR_002798
Software,
algorithm
Volocity 3D
Image Analysis
Software
Perkin Elmer RRID:SCR_002668
Software,
algorithm
ZEN two lite Zeiss RRID:SCR_013672
Other RNasine Plus
RNase Inhibitor
Promega Cat# N261
Other Vectashield
mounting media
Vector
Laboratories, Inc.
Cat# H-1000–10
Other Annexin V, Alexa
Fluor 568 conjugate
Life
Technologies LTD
Cat# A13202 1:20
Other Annexin V, Alexa
Fluor 488 conjugate
Life
Technologies LTD
Cat# A13201 1:20
Continued on next page
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Continued
Reagent type
(species) or resource Designation Source or reference Identifiers
Additional
information
Other Penicillin-Streptomycin
(10,000 U/mL)
Thermo
Fisher
Scientific
Cat# 15140122 Pen: 100 IU/mL
Strep: 100 mg/mL
Other PfuUltra II Fusion
HS DNA Polymerase
Agilent Cat# 600670
Other AnnexinV
binding buffer
Fisher Scientific Cat# BDB556454
Drosophila housekeeping and rearing
Flies were reared at 25˚C under 12 hr/12 hr light/dark cycles on standard oatmeal and molasses
medium (Fernandez-Ayala et al., 2009). Details on fly strains used in this study are presented in the
key resources table and detailed genotypes are included in corresponding figure legends.
For assessment of tumour volume and tumour cell death, flies were transferred to medium
embryo collection cages and allowed to lay eggs for 8 hr at room temperature (RT) on agar/grape
juice plates (2.1% agar, 25% grape juice, 1.25% sucrose, 0.2% methyl 4-hydroxybenzoate) supple-
mented with yeast paste. Plates were kept at 25˚C until hatching. 200 larvae hatched within a 4 hr
time window were collected and transferred to rearing bottles containing 45 mL of fly food to avoid
any developmental delay and/or starvation effects due to overcrowding conditions. The tumour phe-
notype was analysed close to the normal developmental time, i.e. 7 days after hatching. Tumours
were dissected and stained for further analysis (see below).
Generation of defensin mutants
defsk3 and defsk4 mutants were generated using CRISPR/cas9 technology (Hanson et al., 2019).
Mutants were isogenised through backcrosses with a w1118 iso line as previously described in
Ferreira et al. (2014).
Survival assays
Survival of defSK3 animals was compared to wild type controls (isogenised background, iso). Male
flies (5–7 days old) were pricked in the thorax with a needle dipped in a concentrated pellet of fresh
overnight bacterial culture. Infected flies were kept at 29˚C. Listeria innocua was cultured in Brain
heart infusion medium at 37˚C and used at optical density of 200 nm (OD600). Erwinia carotovora car-
otovora 15 was cultured in Luria-Bertani broth at 29˚C and used at OD600 200. Experiments were
repeated three times independently and one representative experiment is shown.
Immunohistochemistry
Tissues were dissected in Phosphate Buffer Saline (PBS) and fixed for 20 min in 4% formaldehyde.
Fat body samples were fixed for 30 min using the same protocol. Tissues were washed three times
in PBS containing 1% of Triton-X100 (PBT) and incubated overnight at 4˚C with primary antibodies.
Tissues were washed five times in PBT and incubated for 2 hr at RT with secondary antibodies and
4’,6-Diamidine-20-phenylindole dihydrochloride (DAPI). After three washes in PBT, tissues were
mounted in Vectashield using Secured-Seal spacers (Thermo Fisher Scientific).
Confocal images were captured using a Zeiss 710 or Zeiss 880 with Airyscan confocal microscope
and processed with Fiji 2.0.0 or Adobe Photoshop C.S5.1.
Quantification of tumour volume and tumour cell death
For analysing tumour phenotype, images were acquired using optimal slice parameter and 12bits
using a Zeiss 710 confocal microscope. Quantifications were made as previously described
(Parisi et al., 2014). Briefly, we used Volocity 3D imaging analysis software to quantify the total vol-
ume of tumour identified by DAPI staining and cell death visualised with anti-Dcp1 staining. When
haltere or leg discs tumours were still associated with the wing disc, they were not considered for
quantification. Quantifications were done in at least three independent biological replicates for each
genetic setting. Single representative experiments are presented except for dlg;def double mutant
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rescue experiments (Figure 2K–L) for which replicates are pooled due to the few larvae available. In
all cases the difference between control and mutant tumour were strongly reproducible between
replicates.
Quantification of colocalisation between Def and Dcp1 or Annexin V
To quantify Def/Dcp-1 and Def/Annexin V colocalisation, we determined the intensity of Def staining
in areas of positive versus negative staining for the second marker using the ImageJ macro, Batch-
Quantify (Johansson et al., 2019).
Sterile rearing conditions
To rule out any effect of infection on the tumour phenotypes, Drosophila larvae were reared on stan-
dard food supplemented with penicillin and streptomycin when indicated in the figure.
qRT-PCR analysis
Total RNA from 7 to 10 whole larvae or tissues collected from 10 to 20 larvae (10 larvae for fat body,
20 larvae for trachea) was extracted using TRIzol according to the manufacturer’s instructions. RNA
was treated with Turbo DNA free Kit and RNA concentration and quality were monitored using a
Nanodrop (Thermo Fisher Scientific). The same amount of total RNA (1 mg for whole larvae and fat
body or 100 ng for trachea) was used to perform the three independent reverse-transcriptions using
the High-Capacity cDNA Reverse Transcription Kit. cDNAs were pooled and qPCR was performed
using PerfeCTa SYBR green following the manufacturer’s instructions. cDNA amplification was moni-
tored with Applied Biosystems 7500 fast instruments. Serial 10-fold dilutions of an external standard
were used to produce a standard curve, and RNA samples were included to control for the absence
of DNA contamination. rpl32 expression was used to normalise expression levels of target genes.
Data was analysed using the Ct method (2-DDct). All qPCR experiments were carried out on three to
seven independent biological replicates (see figure legends for details) and, larvae were sampled
from the same bottle used to analyse the tumour phenotype. GraphPad Prism7 software was used
for graphical representation and statistical analysis. Primer targets and sequences are presented in
key resources table.
PCR amplification of genomic DNA
To verify the sequence of defsk3 and defsk4 mutants, genomic DNA was extracted from single flies
by grinding whole animals with a 200 mL pipette tip containing 50 mL of squishing buffer (10 mM
Tris-HCl pH 8.2, 1 mM EDTA, 25 mM NaCl, 200 mg proteinase K) followed by incubation at 37˚C for
30 min. Proteinase K was heat-inactivated at 95˚C for 2 min. 1 mL of genomic DNA was used for PCR
amplification using PfuUltra II Fusion DNA Polymerase and Eppendorf Mastercycler Ep Gradient
Thermal Cycler.
Annexin V staining and quantification
Tumours were dissected in PBS and incubated in Annexin V binding buffer containing 5% of Alexa
Fluor (488 nm or 568 nm) conjugated Annexin V for 10 min. Tissues were washed quickly in Annexin
V binding buffer and fixed in 4% formaldehyde for 20 min. Immunostaining, mounting and imaging
were then carried out as described above.
We used Fiji 2.0.0 software to quantify Annexin V staining at the tumour surface. Maximal Z-pro-
jection of whole tumours were generated and the Colour Threshold tool was then used to detect
the red pixels that represented Annexin V staining at the surface of tumours. The hue slider was set
to include only the red signal, and the brightness slider was adjusted to exclude any background sig-
nal. This area was then selected and measured in pixels.
Synthetic defensin production and injections
The mature Defensin peptide was synthesised (over 90% purity) and the purity controlled by Gene-
pep using Ultra Performance Liquid Chromatography/Mass Spectrometry. We subsequently com-
pared the integrity of synthetic Defensin with authentic Defensin purified from Drosophila
hemolymph using two complementary approaches, namely Matrix-Assisted Laser Desorption/Ionisa-
tion-Mass Spectrometry (MALDI-MS) for molecular mass determination and trypsin digestion
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followed by nanoLiquid Chromatography/Electrospray Ionisation tandem Mass Spectroscopy
(nanoLC/ESI MS/MS) for molecular integrity confirmation. Those analyses confirmed the similar mass
between natural and synthetic Defensin (respectively provided by Bulet EIRL and Genepep) as well
the presence of disulphide bonds within synthetic Def, demonstrating it is the mature peptide (Data
not shown).
For injection experiments, larvae were collected, washed three times in cold sterile PBS and
injected on a fly pad upon CO2 anaesthesia using Nanoject II (Drummond) and glass capillaries 3.5
inch (Drummond). Larvae were injected with 69 nL of PBS containing 7.5 nmol of synthetic Defensin
or 69 nL of PBS only as control. Larvae were then gently transferred into agar/grape juice plates and
kept at 25˚C. Tumours were dissected 4 hr after injection and stained for visualisation of nuclei and
tumour cell death as describe above.
Statistical analyses
All data are presented as mean ± SD and n values are indicated in the figure legends. Statistical anal-
yses were carried out using GraphPad Prism7 software and only significant differences are indicated
in dot-plots. Survival upon infection was analysed using Log-rank test. qPCR data were analysed
using unpaired t-test with a two-tailed p value. Tumour volume and tumour cell death comparing
two samples were analysed using Mann-Whitney test with a two-tailed p value and the one compar-
ing three genotypes were analysed using One-way ANOVA followed by Turkey’s multiple compari-
sons test. Tumour volume from injected larvae was analysed using Two-way ANOVA followed by
Turkey’s multiple comparisons test and only significant statistical differences between ctrl and Defen-
sin injected larvae for each genotype tested are indicated.
Data and material availability
All raw data is available through http://dx.doi.org/10.5525/gla.researchdata.834.
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